L. Hernandez Borrero

Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation

This study shows that MRTX1133, a KRAS G12D inhibitor, synergizes with 5-FU or ONC212 to reduce tumor cell viability and pERK in CRC and pancreatic cancer cells, regardless of KRAS mutation status.

A subset of CB002 xanthine analogues bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53

The paper identifies CB002 analogues that restore p53 signaling and target an S-phase checkpoint in p53-mutated tumors, inducing apoptosis and reducing proliferation without harming normal cells.